^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CLD-101

    i
    Other names: CLD-101, NeuroNova-1, NNV-1, NSC-CRAd-S-pk7, NSC-CRAd-S-pk7 virotherapeutic, NSCs loaded with CRAd-S-pk7, NSC-CRAd-Survivin-pk7, CRAd-S-pk7 loaded NSCs, CRAd-pk-S-7
    Associations

    News

    Trials
    Company:
    Calidi Biotherap, City of Hope, Northwestern University
    Drug class:
    Stem cell stimulant
    Related drugs:
    Associations

    News

    Trials
    9ms
    Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Northwestern University | Initiation date: Jan 2024 --> Jun 2024
    Trial initiation date • Combination therapy
    |
    CLD-101
    9ms
    Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Aug 2025 | Trial primary completion date: Dec 2023 --> Aug 2025
    Trial completion date • Trial primary completion date • Oncolytic virus
    |
    CLD-101
    1year
    Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Northwestern University
    New P1 trial
    |
    CLD-101
    almost2years
    Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (clinicaltrials.gov)
    P1, N=36, Recruiting, City of Hope Medical Center | Withdrawn --> Recruiting
    Enrollment open
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    CLD-101
    2years
    Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (clinicaltrials.gov)
    P1, N=0, Withdrawn, City of Hope Medical Center | N=30 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Oncolytic virus
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    CLD-101
    over2years
    Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center | Initiation date: Jul 2022 --> Oct 2022
    Trial initiation date • Oncolytic virus
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    CLD-101
    over2years
    Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center | Initiation date: Apr 2022 --> Jul 2022
    Trial initiation date • Oncolytic virus
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    CLD-101
    almost3years
    Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center | Trial completion date: Jun 2023 --> Dec 2023 | Initiation date: Dec 2021 --> Apr 2022 | Trial primary completion date: Jun 2023 --> Dec 2023
    Trial completion date • Trial initiation date • Trial primary completion date • Oncolytic virus
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    CLD-101
    almost3years
    Multiple Treatment Cycles of Neural Stem Cell Delivered Oncolytic Adenovirus for the Treatment of Glioblastoma. (PubMed, Cancers (Basel))
    We recently completed a first-in-human trial assessing the safety of a single intracerebral dose of NSC-delivered CRAd-Survivin-pk7 (NSC.CRAd-S-pk7) combined with radiation and chemotherapy in newly diagnosed high-grade glioma patients...Here, we report IND-enabling studies in which an improvement in treatment efficacy is achieved in immunocompetent mice by administering multiple treatment cycles intracerebrally. The results imply that pre-existing immunity does not preclude therapeutic benefits attainable by administering multiple rounds of an oncolytic adenovirus directly into the brain.
    Journal • Oncolytic virus
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    CLD-101
    3years
    Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, City of Hope Medical Center
    New P1 trial • Oncolytic virus
    |
    BIRC5 (Baculoviral IAP repeat containing 5)
    |
    BIRC5 expression
    |
    CLD-101